"10.1371_journal.pone.0151242","plos one","2016-03-11T00:00:00Z","Fabrice Trovero; Sabrina David; Philippe Bernard; Alain Puech; Jean-Charles Bizot; Jean-Pol Tassin","Key-Obs SAS, Orl√©ans, France; Greenpharma SAS, Orl√©ans, France; Service de pharmacologie, groupe hospitalier Piti√©-Salp√™tri√®re, Paris, France; Sorbonne Universit√©s, Universit√© Pierre et Marie Curie (UPMC) Paris 06, Institut de Biologie Paris Seine (IBPS), UM119 Neuroscience Paris Seine, Paris, France; Institut National de la Sant√© et de la Recherche M√©dicale (INSERM), UMR-S 1130, Neuroscience Paris Seine, Paris, France; Centre National de la Recherche Scientifique (CNRS) UMR 8246, Neuroscience Paris Seine, Paris, France","Conceived and designed the experiments: FT JCB PB AP JPT. Performed the experiments: SD JCB. Analyzed the data: FT JCB PB JPT. Contributed reagents/materials/analysis tools: SD JCB. Wrote the paper: FT JPT JCB AP PB.","Fabrice Trovero, Sabrina David and Jean-Charles Bizot are presently employed by Key-Obs. Philippe Bernard is presently employed by Greenpharma. This commercial affiliation does not alter our adherence to all PLOS ONE policies on sharing data and materials. The data reported in the present article gave rise to published patents (WO2006018538 303 A1 ‚Ä drug for the treatment of central nervous system disorders ‚Ä date 02/23/2006 and WO 2012/175894 A1 ‚Ä Pharmaceutical composition for treating dependency in human beings ‚Ä date 12/27/2012). This does not alter our adherence to PLOS ONE policies on sharing data and materials.","2016","03","Fabrice Trovero","FT",6,TRUE,5,2,4,5,TRUE,TRUE,FALSE,0,NA,FALSE
